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Accumulating work in experimental animals suggests that bradykinin (BK) exerts cardioprotective eﬀects via bradykinin type-2
receptors (BK-2Rs). In human end-stage heart failure, BK-2Rs are signiﬁcantly downregulated by mechanisms that have remained
elusive. Heart tissues from idiopathic dilated cardiomyopathy (IDC; n = 7), coronary heart disease (CHD; n = 6), and normal
patients (n = 6) were analyzed by RT-PCR, SSCP, and Western blotting. In normal and IDC hearts, BK-2R expression increased
with age, with a lower relative increase in IDC hearts. BK-2R mRNA and protein levels showed a positive linear correlation,
suggestingtranscriptionalregulation.Two knownBK-2Rpromoter polymorphisms, −58T/Cand −9/+9, werefound tobepresent
in the study population. The allelic frequencies for the C-allele in −58T/C were 0.58 in normal and CHD hearts and 0.81 in IDC
hearts. Furthermore, the allelic frequencies for the −9 and +9 alleles were 0.42 and 0.58 in normal hearts and 0.64 and 0.36 in IDC
hearts, respectively. All analyzed CHD hearts were homozygous for the −9 allele. Thus, the expression of cardioprotective BK-2Rs
in human hearts is increased with age in normal and IDC hearts and may be regulated on the transcriptional level. Moreover,
comparison of normal subjects and patients with failing hearts revealed diﬀerent allelic frequencies in each of two known BK-2R
gene polymorphisms.
1.Introduction
Accumulating data indicate that bradykinin (BK) exerts
cardioprotectiveeﬀects,whichincludebothprotectionofthe
myocardium from ischemia-reperfusion injuries [1–4]a n d
prevention of left ventricular hypertrophy (LVH) and heart
failure [5–7]. The cardioprotective eﬀects are mainly medi-
ated by the bradykinin type-2 receptor (BK-2R), a member
of the G protein-coupled receptor superfamily, resulting in
vasodilatation, that is release of nitric oxide by endothelial
cells [4, 5, 8], together with both antiproliferative [6, 9]a n d
antihypertrophic [7, 10]e ﬀects on ﬁbroblasts and myocytes.
Inhumanend-stageheartfailure,duetoeitheridiopathic
dilated cardiomyopathy (IDC) or coronary heart disease
(CHD), the amount of cardioprotective BK-2Rs is signif-
icantly decreased [11]. The observed reduction in BK-2R
expression associated with a decrease in endothelial nitric
oxide synthase (eNOS) in the failing hearts and with an
increase in the level of ﬁbrosis in IDC hearts [11].
Although the molecular mechanisms regulating the
expression of BK-2Rs are largely unknown, it is generally
thought that the main regulatory mechanism lies at the
gene expression level [12]. An altered frequency of a
promoter (−58T/C) polymorphism in the BK-2R gene has
been described in hypertensive African-Americans [13],
Japanese [14], and Chinese [15] population, suggesting that
a decreased transcriptional activity in the BK-2R promoter
may be involved in essential hypertension. Accordingly, a
partialgeneticdeﬁciency(heterozygous)ofBK-2Rsinmiceis
already suﬃcient for the onset of mild LVH [16]. Recent data
by Duka et al. have indicated that both BK-1Rs and BK-2Rs
contribute to the maintenance of normal blood pressure in
Wistar rats, but that one receptor can compensate for inhibi-
tion of the other, and that a chronic inhibition of both recep-
tors resulted in signiﬁcant upregulation of related vasoactive
systems [17]. Thus, a decreased expression of BK-2Rs may
be compensated with an increased expression of BK-1Rs.
Furthermore, the +9 allele of a −9/+9 exon 1 polymorphism2 International Journal of Vascular Medicine
of the BK-2R is strongly associated with an increased LV
growth response among normotensive males undergoing
physical training [18], and with impaired LV mass regression
during antihypertensive treatment [19]. In contrast, Fischer
et al. [20] found no relation between the −9/+9 exon 1
polymorphism and the prevalence of myocardial infarction
(MI) nor LV function after MI. However, it is possible that
patients with end-stage heart failure have a genetically deter-
minedfaultintheirBK-2Rexpression,whichcouldaﬀectthe
balance between cardiotoxic and cardioprotective systems, as
well as their individual responses to medical treatments.
In the present study, we have analyzed the age-related
regulation of BK-2R expression and the occurrence of two
known BK-2R promoter polymorphisms in normal and
failing human hearts.
2.MaterialsandMethods
2.1. Preparation of Human Heart Samples. Normal heart
samples (n = 6) were obtained from left ventricles of organ
donors who had no history of cardiac disease and had been
excluded from organ donation because of age, body size,
or tissue type mismatch. The cause of death in the control
patients was subarachnoid hemorrhage (SAH). Sample
collection was performed in accordance with the Helsinki
Declaration, local legislation, and an institutional review
board approved the study protocol. The informed consent
was given by the next of kin prior to organ donation.
Failing left ventricles were harvested at the time of cardiac
transplantation from 13 patients with end-stage heart failure
(New York Heart Association functional class IV) due to
either IDC (n = 7) or CHD (n = 6) at the University Central
Hospital, Helsinki, Finland. All patients were treated with a
combination of drugs including β-blockers, ACE inhibitors,
loop-diuretics, digoxin, and spironolactone. After excision,
the heart tissues were immediately frozen in liquid nitrogen
a n ds t o r e da t−70◦C. Left ventricle myocardium devoid of
visible scar tissue was used in the experiments. The clinical
characteristics of the patients in this study are shown in
Table 1. An institutional review board approved the use of
failing human heart samples.
2.2. Competitive RT-PCR. Total RNA was isolated from
human heart samples using an ultra-pure TRIzol reagent
(GIBCO BRL), and an RNeasy Mini Kit (QIAGEN). One
microgramofpuriﬁedtotalRNAwastranscribedintocDNA,
using a Superscript TM pre-ampliﬁcation system (GIBCO
BRL). The primers were as follows: BK-2R: 5 -CACCAT-
CTCCAACAACTTCG (S), 5 -GGTAGCTGATGACACAA-
GCG (AS); GAPDH: 5 -ACCACAGTCCATGCCATCAC (S),
5 -TCCACCACCCTGTTGCTGTA (AS). The competitor
DNA for the BK-2R was obtained by inserting a 129bp
external DNA fragment into the SacI site. The use of equal
amounts of mRNA in the RT-PCR assays was conﬁrmed
by analyzing the expression levels of glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) (data not shown). The
PCR product was veriﬁed, by DNA sequencing, to represent
the corresponding target and quantitated with a Gel Doc
2000gel documentation system (Bio-Rad). The logarithm
Table 1: BK-2R polymorphism in human hearts. The presence of
two BK-2R gene polymorphisms, −58T/C and −9/+9, was analyzed
in normal and failing human hearts according to the protocol
described in Section 2.




M1 9 T / C + 9 / −9
2 M 43 T/C +9/+9
3 M 49 C/C +9/−9
4M 3 1 T / T −9/−9
5 M 40 T/C +9/+9
6 F 50 C/C +9/−9
7
CHD
M6 1 T / C −9/−9
8M 6 0 T / T −9/−9
9M 5 5 C / C −9/−9
10 M 52 T/C −9/−9
11 M 60 C/C −9/−9
12 M 54 T/C −9/−9
13
IDC
M2 9 C / C −9/−9
14 M 60 C/C −9/−9
15 M 46 C/C +9/−9
16 M 56 C/C +9/−9
17 M 55 T/T +9/−9
18 M 56 T/C +9/−9
19 M 63 C/C +9/−9
of the target-to-competitor ratio was plotted against the
logarithm of the competitor DNA-molecules [11].
2.3. Detection of a −/ + 9P o l y m o r p h i s mi nE x o n1o fB K - 2 R
GenebyPCR. GenomicDNAwasisolatedfromhumanheart
tissue using an RNA/DNA Mini Kit (Qiagen) and stored in
TE buﬀer (pH 8.5) in aliquots at −20◦C.
Isolated genomic DNA was subjected to PCR using
primers spanning the insertion/deletion (−/+9bp) site in
exon 1 of the BK-2R gene. The primers were as fol-
lows: BK-2R: 5 -CAAAGATGAGCTGTTCCCGCC (S), 5 -
GGGAACTTTTCCCAACTCCCC (AS). The PCR was run at
Tm = 66
◦C for 40 + 1 cycles and the obtained PCR products
were separated on a 3% MetaPhor agarose gel (BMA).
2.4. Detection of a −58T/C BK-2R Promoter Polymorphism
by PCR and SSCP. Genomic DNA was isolated as described
above and subjectedto PCR using following primers: BK-2R:
5 -AGGAGTGCAGAGCTCAGCTGGAG (S), 5 -TCGGAG-
CCCAGAAGCCAGAG (AS). The obtained PCR products
were denatured by heating at 94◦C for 3 minutes in 95%
formamide, 10mM NaOH, 0.25% bromphenol blue, and
0.25% xylene cyanol, and then were rapidly cooled on ice.
The denatured PCR samples were mixed with 9 parts of
SSCP Sucrose Dye (10g sucrose, 62.5mg BPB.XC, 0.5ml
0.5MEDT A(pH8.0)in25mldH 2O), and run on a 14%
acrylamide/bis (29:1) gel (BIORAD) containing 10% (v/v)
2x concentrated MDE gel solution (BMA) for 5min at 500V,
and then for 19 hours at 250V at room temperature. The gel
wasstainedwithSYBRGoldnucleicacidgelstain(MolecularInternational Journal of Vascular Medicine 3










































































Figure 1: BK-2R mRNA expression correlates with age in normal
and failing (IDC) hearts. The level of BK-2R mRNA expression
was plotted against age of normal, IDC, and CHD hearts, and the
correlation was calculated. P<0.05 was considered signiﬁcant.
Probes) for 30–40min and analyzed with a Gel Doc 2000gel
documentation system (Bio-Rad).
3. Statistics
The data was subjected to linear regression analysis. Statisti-
cal signiﬁcance was accepted at P<0.05.
4. Results
4.1. BK-2R Expression Increases with Age in Normal and IDC
Hearts. Bysimplelinearregressionanalysis,astrongpositive
correlation (r = 0.827; P<0.05) was found between the
level of BK-2R mRNA expression and age in normal human
hearts (Figure 1, upper panel), suggesting that normal hearts
adapttoage-relatedchangesbyincreasingtheirexpressionof
cardiacBK-2Rs.Inaddition,asigniﬁcantpositivecorrelation
(r = 0.951; P<0.001) was also seen between the level
of BK-2R mRNA expression and age in the IDC hearts
(Figure 1, middle panel). However, the relative increase in
BK-2R mRNA expression, that is the slope of the regression
curve, was signiﬁcantly lower in the IDC hearts than in the
normal hearts. Surprisingly, a mild negative correlation (r =
0.509) was found between BK-2Rs mRNA and age in the
C H Dh e a r t s( Figure 1, bottom panel), suggesting a disease-
dependent suppression of BK-2R expression. On account
of the nature of the disease, all the CHD hearts were from
patients older (>50 years) than those in the normal group.
4.2. Linear Correlation between BK-2R mRNA and Protein
Expression. By further plotting the BK-2R protein levels
against age of the patients (Figure 2(a)) and the BK-2R
mRNA levels against the receptor protein levels of both
normal and failing hearts (n = 18) (Figure 2(b)), we found
a positive linear correlation (R = 0.761, P<0.001) between
the mRNA and protein levels. This result suggests that the
expression of BK-2Rs in both normal and failing human
hearts may be regulated on the transcriptional level, rather
than on the translational level.
4.3. BK-2R Polymorphism in Failing Human Hearts. To
further analyze the possible transcriptional mechanisms
involved in the observed downregulation of BK-2R expres-
sion in failing hearts, we determined the presence of two
polymorphisms, a −58T/C promoter polymorphism and a
9 base pair (bp) exon 1 deletion/insertion polymorphism,
both previously known to aﬀect the BK-2R expression levels
(Table 1). The characteristics of the analyzed patients as well
as the presence of the two analyzed BK-2R polymorphisms,
are described in Table 1. As shown in Tables 1 and 2, the
genotypic frequency of CC in the IDC hearts (71%) was
signiﬁcantly increased, as compared to the normal hearts
(33%). In contrast, the frequency of the TT genotype was
found to be similar in both IDC (14%) and normal (17%)
hearts, whereas the TC genotype dominated in the normal
hearts (50%), as compared to the IDC hearts (15%). The
genotypic frequencies in the CHD hearts were identical to
the normal hearts, that is, 33% were CC, 17% were TT,
and 50% were TC. Furthermore, the allelic frequencies of
the −58T/C promoter polymorphism were 0.58 for the C-
allele and 0.42 for the T-allele in both normal and CHD
hearts. In contrast, the allelic frequencies in IDC hearts were
0.81 for the C-allele and 0.19 for the T-allele. In terms
of the 9-bp exon 1 deletion/insertion polymorphism, we
found that all patients in the CHD group (100%) were
homozygous for the deletion (−9/−9) (Table 2). In contrast,
in the normal group, only 17%, and in the IDC group,
29% were homozygous for the 9bp deletion. Among the
IDC hearts, 71% were heterozygous, whereas, in the normal
hearts,50%werefoundtobeheterozygous(−9/+9)and33%
were homozygous for the +9 allele.
5. Discussion
Here we show that a linear relationship between BK-2R
mRNA and protein expression exists in normal and failing
human left ventricles, suggesting that the expression of
cardioprotective BK-2Rs in human myocardium may be













































































































Figure 2: (a) BK-2R protein levels in normal and failing hearts
show a linear trend (not signiﬁcant) when plotted against age.
(b) BK-2R mRNA expression levels plotted against BK-2R protein
levels show a positive linear correlation (R = 0.761, P<
0.001), suggesting that BK-2R expression may be regulated on the
transcriptional level.
translational level. In addition, in normal and IDC hearts,
the BK-2R expression was found to correlate positively with
age, but the relative increase was clearly lower in the IDC
Table 2: Genotypic and allelic frequencies of two BK-2R gene poly-
morphisms in normal and failing human hearts. The genotypic and
allelic frequencies for two common BK-2R gene polymorphisms
were calculated in both normal and failing human hearts.
(a)
Polymorphism Genotype Normal IDC CHD
−58T/C
T/T 17.0% 14.0% 17.0%
T/C 50.0% 15.0% 50.0%
C/C 33.0% 71.0% 33.0%
−9/+9
−9/−9 17.0% 29.0% 100%
−9/+9 50.0% 71.0% 0%
+9/+9 33.0% 0% 0%
(b)
Polymorphism Allele Frequency
Normal IDC CHD Average
−58T/C C-allele 0.58 0.81 0.58 0.66
T-allele 0.42 0.19 0.42 0.34
−9/+9
−9-allele 0.42 0.64 1.00 0.69
+9-allele 0.58 0.36 0.00 0.31
hearts than in the normal hearts. The increased presence of
the C-allele in the IDC hearts may explain the age-related
lower relative increase in BK-2R expression in IDC hearts,
as compared to normal hearts. These results suggest that the
human heart adapts to age-related changes in heart function
[21] by upregulating the expression of cardioprotective BK-
2Rs. This is consistent with previous studies performed with
BK-2R KO mice, which in the absence of BK-2Rs show an
accelerated ageing phenotype [16, 22]. Moreover, in a recent
study, BK was shown to protect against ROS-mediated DNA
damage and reduce endothelial cell senescence via BK-2R
and NO-dependent pathway, supporting an important role
for BK and BK-2Rs in ageing processes [23].
In a recent study, a correlation between age and the
expression of BK-1Rs and BK-2Rs has also been observed in
male Brown Norway rats [24]. The authors showed that the
expression of BK-2Rs was decreased in rat hearts as a func-
tion of age, whereas the expression of BK-1Rs was increased.
Hence, they suggested that the age-related decrease in BK-
2Rs is cardiotoxic and that the increased expression of
BK-1Rs may be a compensatory eﬀect. Similarly, in our
previous studies, we observed an age-related decrease in
both mRNA and protein expression of BK-2Rs in normal
Wistar-Kyoto rats (WKYs) [25]. However, in contrast to
normotensive WKYs, spontaneous hypertensive rats (SHRs),
that is, rats with a hypertensive phenotype, showed an age-
related increase in BK-2R mRNA expression. Interestingly,
also BK-2R protein levels increased in the SHRs during the
ﬁrst half of their lifespan, that is, during the LVH stage, but
were signiﬁcantly decreased in the failing rat hearts [25].
In our present human studies, the expression of BK-2Rs
increasedwithincreasingageinboththecontrolandtheIDC
group, whereas a relative decrease in BK-2Rs was observed in
the CHD study group.International Journal of Vascular Medicine 5
It seems evident that LVH may develop as a compen-
satory mechanism during the early stages of the disease,
whereas the later stages are characterized by a maladaptive
loss of myocytes with subsequent ﬁbrosis, LV dysfunction,
and heart failure. Thus, if BK-2Rs are an essential part of
a local cardioprotective system, a logical adaptive response
to an ongoing pathological process would be an increased
expression of BK-2Rs. Therefore, it is possible that BK-2R
expression is upregulated during LVH, and that the observed
receptor downregulation occurs only later, at the stage of
heart failure. Similarly, the increased expression of BK-2Rs
with increasing age in normal human hearts may occur as
an adaptive response to an age-related physiologic process of
disease-independent ﬁbrosis [23]. It therefore seems unlikely
that the observed down-regulation of BK-2Rs in the failing
hearts is due merely to the greater age of the patients. This,
however,isclearlydiﬀerentfromnormotensiverats,inwhich
the expression of BK-2Rs is decreased with increasing age
[24, 25]. The increased levels of ﬁbrosis observed in the
IDC hearts [11]i nr e l a t i o nt oar e d u c t i o ni nt h en u m b e ro f
myocytes may partly also explain the reduced amount of BK-
2Rs in the IDC hearts, however; this may not hold true for
the CHD hearts, since no increase in ﬁbrosis was observed in
CHD hearts [11].
Recent studies have suggested that patients developing
LVH and heart failure may have a genetic background in
which their expression levels of cardioprotective BK-2Rs are
signiﬁcantly weaker than in normal hearts, or completely
lacking. Indeed, the C allele of the −58T/C promoter
polymorphism in the BK-2R gene has been associated with
the occurrence of essential hypertension in several ethnic
groups, including African Americans [13], Japanese [14],
and Chinese [15] populations. Our present results also sug-
gestthattheexpression ofBK-2Rsin IDCheartsis associated
with the C allele of the –58T/C promoter polymorphism and
are the ﬁrst to suggest that this allele is accumulated in IDC
patients and may partially explain the observed reduction
in BK-2R expression in this patient group [11]. In contrast,
the distribution of the C allele in CHD hearts is similar to
the distribution in normal hearts, although the expression of
BK-2Rs appears negatively correlated with age in the CHD
group.
Military trainees, which were homozygous for the −9
allele and underwent physical training, did not develop
exercise-induced myocardial hypertrophy to a similar extent
as heterozygous subjects or homozygous for the +9 allele
[18]. This result suggests that the −9 allele suppresses
physiological LV hypertrophy induced by physical training,
whereas the +9 allele may associate with increased phys-
iological hypertrophy, and possibly also with pathological
hypertrophy.Indeed,itwasrecentlyshownthatpatientswith
a +9/+9 genotype and suﬀering from essential hypertension
responded poorly in LV mass regression, independent of
blood pressure reduction or treatment, as compared to
other genotypes [19]. In the present work, none of the
IDC and CHD hearts were homozygous for the +9/+9
genotype, whereas 33% of the normal hearts were +9/+9
genotypes. This result contradicts previous studies, in which
the +9/+9 genotype has been linked to increased exercise-
induced physiological LV hypertrophy in normotensive sub-
jects and to poor LV mass regression during antihypertensive
treatment. However, the question remains whether the
mechanisms involved in the progression of physiological
andpathophysiologicalLVhypertrophydiverge,andwhether
also the cardioprotective mechanisms vary depending on the
initial cause of the disease? Similarly, the contribution of BK-
2R polymorphisms in the development of LV hypertrophy
and heart failure may diﬀer between CHD hearts and IDC
hearts. These statements remain to be considered in future
experiments.
6. Limitationsof the Study
The number of human heart samples in this study is too low
to allow any conclusions regarding the general distribution
of the studied polymorphisms in failing hearts on the
population level. Future studies should aim at analyzing the
correlation between IDC and CHD patients and speciﬁc
promoter polymorphisms capable of aﬀecting the expression
of BK-2Rs in a large clinical setting. However, due to
the advancement of various preventive treatment modes of
coronary heart disease, particularly the use of statins, the
number of CHD patients subjected to transplantations per
year has dramatically dropped. Thus, most of the patients
undergoing heart transplantation are diagnosed with pri-
mary myocardial disease. Also, acute coronary syndromes
hardly lead to massive myocardial necrosis any more. Finally,
patients with multiple myocardial infarctions and ensuing
end-stage heart failure are also very rare, and if patients have
a severe heart failure due to CHD, they are too old for heart
transplantation.
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